证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2023-017 R特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他：电话会议 首创证券：王斌；太平洋证券：周豫、刘哲涵；华夏基金： 参与单位名称及 胥梦缘；建信基金：郑丁源；相聚资本：邓巧 人员姓名 （以上排名不分先后） 时间 2023年12月 地点 北京 董事会秘书：于海波 ...

一、本次股份解除质押的基本情况 本次解除质押股份暂无后续质押计划。后续如有相关质押情形，公司将根据 相关法律法规要求及时履行信息披露义务。 证券代码：603676 证券简称：卫信康 公告编号：2023-036 西藏卫信康医药股份有限公司 关于控股股东股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 西藏卫信康医药股份有限公司（以下简称"公司"）控股股东西藏卫信 康投资管理有限公司（以下简称"西藏卫信康投资"）持有公司股份 205,248,960 股，占公司总股本的 47.17%；本次解除质押 5,390,000 股后，西藏卫信康投资 持有的公司股份累计质押 0 股，占其持有公司股份的 0.00%，占公司总股本的 0.00%。 2023 年 11 月 17 日，公司获悉控股股东西藏卫信康投资所持本公司的部分 股份已办理完成解除质押手续，具体事项如下： | 股东名称 | 西藏卫信康投资 | | --- | --- | | 本次解除质押股份 | 5,390,000 股 | | 占其所持股份比例 | ...

Financial Performance - In the first three quarters of 2023, the company achieved a revenue of 1.061 billion yuan, a year-on-year decrease of 0.56% [3] - The net profit attributable to shareholders was 210 million yuan, reflecting a year-on-year increase of 39.24% [3] Business Strategy - The company adheres to the corporate spirit of "responsibility, sharing, credibility, and innovation" and aims to "care for life and maintain health" [3] - It focuses on R&D innovation, combining generic and innovative products to enhance its technological capabilities and expand into differentiated markets [3] Product Development - The company has recently approved a multi-vitamin injection (13) for intravenous use, aimed at preventing vitamin deficiencies in adults and children aged 11 and above [4] - The core products utilize an API+ formulation development model, with limited impact from raw material price fluctuations due to in-house production [3] Investor Engagement - The company expressed gratitude to investors for their trust and support during the Q3 earnings presentation [2] - The management team, including the chairman and independent directors, engaged in a Q&A session to address investor concerns and feedback [3][4]

证券代码：603676 证券简称：卫信康 西藏卫信康医药股份有限公司 投资者关系活动记录表 编号：2023-015 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 R其他：电话会议 东吴证券：宋金洋；华福证券：王帅；国元证券：马云涛； 国盛证券：张金洋、胡偌碧、陈欣黎；天风证券：曹文清； 华创证券：朱珂琛；德邦证券：李强、吴沛柯；信达证券： 宋丹；招商证券：焦玉鹏；首创证券：王斌；太平洋证券： 周豫；华西证券：徐顺利；浙商医药：郭双喜、盖文化；渤 海人寿：王森；正圆投资：熊小铭；红马投资：李伟；承珞 投资：林田心；青骊投资：罗晓梅；天弘基金：王斌；长城 基金：龙宇飞；国联基金：陈浩；融通基金：武霆威；光大 保德信基金：高睿婷；嘉实基金：马延超；亚太财险：田春 ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 311,769,753.60, a decrease of 21.89% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was CNY 76,239,537.78, an increase of 58.78% year-on-year[5]. - The basic earnings per share for Q3 2023 was CNY 0.18, representing a 63.64% increase compared to the same period last year[6]. - Total operating revenue for the first three quarters of 2023 was approximately CNY 1.06 billion, a slight decrease of 0.07% compared to CNY 1.07 billion in the same period of 2022[17]. - Net profit for the first three quarters of 2023 was approximately CNY 210.24 million, representing a significant increase of 39.25% compared to CNY 150.99 million in the same period of 2022[19]. - Basic and diluted earnings per share for the third quarter of 2023 were both CNY 0.49, an increase from CNY 0.35 in the same period of 2022[20]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to CNY 1,771,936,303.69, reflecting a 6.44% increase from the end of the previous year[6]. - The total number of ordinary shareholders at the end of the reporting period was 16,458[10]. - The company's total current assets reached RMB 1,213,657,699.80, compared to RMB 1,138,971,908.94 at the end of 2022, indicating an increase of about 6.6%[13]. - Total liabilities decreased to RMB 427,689,012.51 from RMB 444,132,719.59, showing a reduction of about 3.7%[15]. - The total assets as of Q3 2023 amounted to ¥1,665,423,374.91, a slight increase from ¥1,664,718,174.54 at the end of 2022, reflecting a growth of approximately 0.04%[26]. - The total liabilities were reported at ¥411,797,328.39, unchanged from the previous year, indicating stable liability management[26]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY 161,981,748.26, showing a decrease of 11.33%[6]. - The net cash flow from operating activities for Q3 2023 was ¥161,981,748.26, a decrease from ¥182,683,255.63 in Q3 2022, reflecting a decline of approximately 11.5%[22]. - The cash inflow from operating activities for the first three quarters of 2023 was approximately CNY 1.15 billion, an increase from CNY 1.12 billion in the same period of 2022[21]. - The cash outflow from financing activities was ¥96,021,785.53, compared to ¥73,940,761.18 in Q3 2022, marking an increase of about 30.0%[22]. Expenses - Research and development expenses for the first three quarters of 2023 were approximately CNY 70.17 million, an increase of 71.73% compared to CNY 40.82 million in the same period of 2022[18]. - Sales expenses decreased to approximately CNY 190.57 million in the first three quarters of 2023, down 18.87% from CNY 234.93 million in the same period of 2022[18]. - The company reported a tax expense of approximately CNY 8.16 million for the first three quarters of 2023, a decrease from CNY 8.75 million in the same period of 2022[19]. Equity and Retained Earnings - The equity attributable to shareholders at the end of Q3 2023 was CNY 1,344,247,291.18, up 10.13% from the end of the previous year[6]. - The company’s retained earnings increased significantly to RMB 502,061,102.55 from RMB 392,896,638.00, reflecting a growth of approximately 27.9%[15]. - The total owner's equity (or shareholder's equity) was 1,220,585,454.95, reflecting stability in shareholder value[27]. Other Comprehensive Income - The company’s other comprehensive income rose to RMB 21,323,107.34 from RMB 14,052,964.47, indicating an increase of around 51.8%[15]. - Other comprehensive income after tax for the first three quarters of 2023 was approximately CNY 8.17 million, down from CNY 12.95 million in the same period of 2022[19].

证券代码：603676 证券简称：卫信康 公告编号：2023-035 西藏卫信康医药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 10 月 25 日(星期三)至 10 月 31 日(星期二)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过西藏卫信康医药股份 有限公司（以下简称"公司"）邮箱 wxk@wxkpharma.com 进行提问。公司将在信 息披露允许的范围内，在说明会上对投资者普遍关注的问题进行回答。 公司已于 2023 年 10 月 25 日发布公司 2023 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况，公司计划于 2023 年 11 月 1 日 15:00-16:00 举行 2023 年第三季度业绩说明会，就投资者关 心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开 ...

Group 1: Company Overview - The company is Xizang Weixin Kang Pharmaceutical Co., Ltd. with stock code 603676 [1] - The company held investor relations activities in September 2023, including strategy meetings with various securities and asset management firms [2] Group 2: Sales Performance - Revenue from the injection of multiple vitamins (12) reached approximately 542.62 million yuan, accounting for 72.41% of the company's total revenue [3] - The sales from the alliance region in Henan province contributed about 30.08% to the company's total revenue [3] Group 3: Market Strategy and Coverage - As of June 2023, the injection of multiple vitamins (12) was covered in over 2,400 hospitals, primarily in secondary and tertiary hospitals [3] - The company plans to enhance market share through reasonable market strategies despite a decrease in the winning price compared to the original benchmark price [3] Group 4: Product Development and Future Opportunities - The company has recently approved potential products, including pediatric compound amino acid injection (19AA-I) and other electrolyte solutions, which are expected to contribute to revenue growth [3] - The concept of nutritional therapy is evolving, indicating a promising long-term development trajectory for the industry [4]

西藏卫信康医药股份有限公司 关于参与十九省(区、兵团)药品联盟集中带量采购拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，西藏卫信康医药股份有限公司（以下简称"公司"）合作生产企业山西普德 药业有限公司（以下简称"普德药业"）参与了河南、山西、内蒙古、辽宁、吉林、黑 龙江、安徽、江西、湖南、广西、海南、贵州、云南、西藏、陕西、青海、宁夏、新疆、 新疆生产建设兵团等（以下简称"联盟地区"）十九省(区、兵团)药品联盟集中带量采 购（以下简称"联盟集采"）的投标，根据河南省医疗保障局 2023 年 8 月 30 日发布的 《十九省(区、兵团)药品联盟集中带量采购拟中选结果》，公司与普德药业的合作生产 产品注射用多种维生素（12）拟中选本次联盟集采，现将相关情况公告如下： 证券代码：603676 证券简称：卫信康 公告编号：2023-033 约定采购量，超出部分中选企业仍应按中选价足量供应，医疗机构仍应优先采购中选产 品，直至采购周期届满。 二、本次药品拟中选对公司的影响 2022 年，公司通过合作生产产品注射用多 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 749.41 million, an increase of 12.18% compared to CNY 668.04 million in the same period last year[21]. - Net profit attributable to shareholders increased by 30.13% to CNY 134.00 million from CNY 102.97 million year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 131.46 million, up 29.32% from CNY 101.66 million in the previous year[21]. - The basic earnings per share rose to CNY 0.31, reflecting a 29.17% increase from CNY 0.24 in the same period last year[22]. - The weighted average return on net assets improved to 10.50%, an increase of 1.30 percentage points compared to 9.20% in the previous year[22]. - The company achieved a revenue of 749 million yuan in the reporting period, representing a year-on-year growth of 12.18%[49]. - Net profit attributable to shareholders reached 134 million yuan, an increase of 30.13% year-on-year, while the net profit excluding non-recurring gains and losses was 131 million yuan, up 29.32%[49]. Research and Development - Research and development expenses increased by 72.24% to ¥41,680,751.62 from ¥24,199,217.07, primarily due to increased R&D investments[58]. - The company has over 40 ongoing major research projects, with expectations for 1-2 products to receive approval in the second half of 2023[52]. - The company has established three core technology platforms: new injection technology, complex formulation technology, and new freeze-drying technology, enhancing its R&D capabilities[48]. - The research and development strategy focuses on independent innovation, targeting high-demand, high-tech, and low-competition products, with a structured approach to product pipeline management[42]. - The company is actively involved in research and development to innovate new nutritional therapies for critical care patients[36]. Product Development and Market Strategy - The company focuses on the research, production, and sales of chemical pharmaceuticals, with a strong competitive edge in compound vitamins, trace elements, and electrolyte solutions[32]. - The company has developed a product matrix including injectable multivitamins and various electrolyte solutions, aimed at meeting unmet clinical needs[33]. - The company is positioned to leverage the growing demand in the healthcare sector, driven by an aging population and ongoing medical reforms[27]. - The company is committed to enhancing its clinical value and meeting the evolving needs of the healthcare market through continuous innovation[32]. - The company has implemented a stock incentive plan to optimize its compensation structure and maintain the stability of its core team[48]. Financial Position - Total assets at the end of the reporting period were CNY 1.70 billion, a 2.12% increase from CNY 1.66 billion at the end of the previous year[21]. - Net assets attributable to shareholders increased by 3.53% to CNY 1.26 billion from CNY 1.22 billion at the end of the previous year[21]. - Cash and cash equivalents at the end of the period amounted to ¥404,983,520.34, representing 23.82% of total assets, a decrease of 22.02% compared to the previous year[61]. - Accounts receivable increased to ¥276,224,264.07, accounting for 16.25% of total assets, reflecting a 26.00% increase due to higher sales[61]. - Total liabilities decreased to CNY 436,226,952.33 from CNY 444,132,719.59, showing a reduction of about 1.8%[125]. Operational Challenges and Risks - The company has not disclosed any major risks that could significantly impact its operations during the reporting period[6]. - The company is facing policy risks due to regulatory changes in the pharmaceutical industry, which may impact operational models[71]. - The company faces long-term risks of price reductions for its products due to regulatory measures aimed at controlling medical costs, which may adversely affect profitability[74]. - The company acknowledges the high investment and risk associated with drug development, implementing risk assessment and control mechanisms to manage uncertainties in the R&D process[76]. Environmental and Social Responsibility - The company has achieved zero accidents and zero incidents of occupational diseases in the first half of 2023, reflecting its commitment to safety and health management[85]. - The company has implemented a comprehensive pollution prevention system and strictly adheres to environmental protection laws, completing the permit change for wastewater discharge during the reporting period[86]. - The company has invested a total of 70,344.62 yuan in poverty alleviation and rural revitalization projects, including 19,300.00 yuan in cash donations[98]. - The company has established a safety and environmental protection department to oversee daily environmental protection efforts and enhance organizational capabilities[87]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 11,839[113]. - The largest shareholder, Tibet Weixin Kang Investment Management Co., Ltd., holds 205,248,960 shares, representing 47.17% of total shares[115]. - The report indicates no changes in the shareholding of the top shareholders during the reporting period[116]. - The company has committed to avoiding any competition with its controlling shareholders and related parties, ensuring no direct or indirect business operations that may compete with the company's business[102]. Compliance and Governance - The company adheres to the accounting standards and reflects its financial status, operating results, and cash flows accurately[167]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[92]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[106].

证券代码：603676 证券简称：卫信康 公告编号：2023-028 西藏卫信康医药股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 西藏卫信康医药股份有限公司（以下简称"公司"）第三届监事会第七次会 议通知于 2023 年 8 月 11 日以邮件的形式送达全体监事。会议于 2023 年 8 月 22 日以现场记名投票表决的方式召开。会议由公司监事会主席宁国涛主持，应出席 监事 3 名，实际出席监事 3 名。本次会议的参与表决人数及召开程序符合《公司 法》和《公司章程》的有关规定，合法有效。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《2023 年半年度报告（全文及摘要）》。 表决结果：3 票同意、0 票反对、0 票弃权。 （二）审议通过了《2023 年半年度募集资金存放与实际使用情况的专项报 告》 监事会认真审阅了公司 2023 年半年度募集资金存放与实际使用情况的专项 报告，认为公司募集资金的管理和使用履行了相关的审批 ...